
    
      Phase 1: Multicenter, repeated administration, disclosure, dose escalation, Evaluate safety
      and tolerability and explore efficacy

      Phase 2a: Multicenter, repeated administration, random assignment, double blinding, parallel,
      Efficacy and safety are evaluated for repeated administration compared to placebo and single
      administration.
    
  